On March 22, 2019 IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") reported financial results for the fourth quarter and twelve-month periods ended December 31, 2018 (Press release, IntelGenx, MAR 22, 2019, View Source [SID1234534569]). All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
2018 Fourth Quarter Financial Summary:
Revenue was $650,000, compared to $1.5 million in the 2017 fourth quarter
Adjusted EBITDA was ($2.0 million), compared to ($600,000) in Q4-2017
Cash and short-term investments totaled $11.0 million as at December 31, 2018
2018 Full-Year Financial Summary:
Revenue was $1.8 million, compared to $5.2 million in 2017
Net comprehensive loss was $10.7 million, compared to net comprehensive loss of $2.7 million in 2017
Adjusted EBITDA was ($7.9 million), compared to ($1.4 million) in 2017
Recent Operational Highlights:
Announced U.S. Food and Drug Administration ("FDA") acceptance of the RIZAPORT New Drug Application ("NDA") resubmission and the Agency’s assignment of a Prescription Drug User Fee Act ("PDUFA") goal date of April 1, 2019
Partnered with Gensco Pharma to market RIZAPORT in the United States
Announced FDA pre-approval inspection of IntelGenx’s facility related to the RIZAPORT NDA
Granted Japanese patent for RIZAPORT VersaFilm
Began Montelukast VersaFilm dosing in patients with mild to moderate Alzheimer’s Disease in Phase 2a study
Announced Montreal’s Douglas Mental Health University Institute as ninth Montelukast VersaFilm Phase 2a clinical trial site
"The agreements we secured with Tilray and Gensco Pharma in 2018 represented an important inflection point for IntelGenx as we advanced our strategy to commercialize our pipeline of innovative oral film products with strong partners," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "We have a very positive outlook for 2019 and 2020 and look forward to updating our stakeholders as we make progress towards achieving a number of key development and commercialization milestones."
Financial Results:
Total revenues for the three-month period ended December 31, 2018 amounted to $650,000, a decrease of $850,000 compared to $1.5 million for the three-month period ended December 31, 2017. The change is mainly attributable to a decrease in deferred revenues partially offset by an increase in R&D revenues. Operating costs and expenses were $2.9 million for the fourth quarter 2018, versus $2.3 million for the corresponding three-month period of 2017. For Q4-2018, the Company had an operating loss of $2.2 million, compared to operating income of $850,000 for the comparable period of 2017.
Total revenues for the twelve-month period ended December 31, 2018 amounted to $1.8 million, compared to $5.2 million for the twelve-month period ended December 31, 2017. Operating costs and expenses were $10.8 million for the full year 2018, versus $7.7 million for the corresponding 12-month period of 2017. For the twelve-month period of 2018, the Company had an operating loss of $9.0 million, compared to an operating loss of $2.5 million for the comparable period of 2017. Net comprehensive loss was $10.7 million, or $0.14 per basic and diluted share, for the twelve-month period of 2018, compared to net comprehensive loss of $2.7 million, or $0.04 per basic and diluted share, for the comparable period of 2017.
As at December 31, 2018, the Company’s cash and short-term investments totalled $11.0 million, compared with $4.9 million as at December 31, 2017.
Annual Filings:
The Company’s annual report on Form 10-K and financial statements for the year ended December 31, 2018 as well as the 2019 Proxy Statement, will be filed with the United States Securities and Exchange Commission and the Canadian Securities regulatory authorities today, Friday, March 22, 2019.
Conference Call Details:
IntelGenx will host a conference call to discuss these 2018 fourth quarter and full year financial results on Monday, March 25, 2019, at 8:00 a.m. EDT. The dial-in number for the conference call is (833) 231-8269 (Canada and United States) or (647) 689-4114 (International), conference ID 1297963. The call will be also be webcast live and archived at www.intelgenx.com.